

P.2.2 AD versus DLB

P.2.2.1 Amyloid Beta 1-42

Studies	Design	Total N	Sens (95%CI)	Spec (95%CI)	Measure	Summary of findings (95%CI)	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Quality
SECONDARY CARE												
1 study (Andreasen 2001)	Prospective	172	0.65 (0.57, 0.72)	0.67 (0.33, 0.89)	LR+	1.95 (0.77, 4.95)	Not serious	n/a	Not serious	Serious	-	MODERATE
					LR-	0.52 (0.32, 0.87)	Not serious	n/a	Not serious	Serious		MODERATE